Report of a WHO informal consultation on preclinical and clinical aspects of the use of immunomodulators in HIV infection. Geneva, 3-5 April 1989. World Health Organization Global Programme on AIDS.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Report of a WHO informal consultation on preclinical and clinical aspects of the use of immunomodulators in HIV infection. Geneva, 3-5 April 1989. World Health Organization Global Programme on AIDS.

AIDS. 1990 Dec;4(12):WHO1-14. Unique Identifier : AIDSLINE MED/91207609

Abstract: A wide spectrum of immunomodulatory strategies offer promise for treating people with HIV infection; however, numerous gaps still exist in our understanding of the normal regulation of the immune system during the progression of HIV infection. Preclinical development of immunomodulators must include a strong rationale for the use of the immunomodulating substance substantiated by appropriate laboratory studies, in vitro as well as in vivo. Preclinical studies must demonstrate the safety of the proposed therapeutic agent, including an assessment of the potential for adverse effects on immune function and virus replication. Combined therapeutic modalities should also be appropriately evaluated at the preclinical level. Clinical evaluations should be instituted only after a strong rationale is substantiated and safety concerns are fully considered. Initial studies should be conducted with patients at an intermediate stage of HIV disease progression. Immunomodulators may exhibit unusual dose-response patterns, and this should be considered when designing the trials. The consultation recommended that WHO continue to provide a forum for the timely exchange and validation of information related to the development and clinical evaluation of immunomodulators for the treatment of individuals infected with HIV.

Keywords: Adjuvants, Immunologic/*THERAPEUTIC USE Clinical Trials Drug Evaluation Human HIV Infections/IMMUNOLOGY/*THERAPY Immunotherapy World Health Organization CONSENSUS DEVELOPMENT CONFERENCE JOURNAL ARTICLE REVIEW

910830
M9180961

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .